Olmesartanmedoxomil/Amlodipin Viatris (Olmesartan Medoxomil, Amlodipine)

Olmesartan medoxil, the active ingredient in Olmesartanmedoxomil/Amlodipin Viatris, is a angiotensin II receptor blocker presented as a oral tablet for hypertension management in adults. It combines olmesartan medoxil with amlodipine, a calcium‑channel blocker, to provide complementary blood‑pressure control.

GNH USA supplies Olmesartanmedoxomil/Amlodipin Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartanmedoxomil/Amlodipin Viatris is indicated for the treatment of hypertension, acting on the renin‑angiotensin system and vascular smooth‑muscle tone. - Hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Hypertension with high cardiovascular risk: provides additional protection against stroke and myocardial infarction. - Hypertension in patients requiring combination therapy: simplifies treatment by combining an ARB with a calcium‑channel blocker.

Adverse reactions may occur with any antihypertensive regimen.

Common Side Effects: - Dizziness or light‑headedness - Headache - Peripheral edema - Flushing - Fatigue - Nasal congestion

Serious or Rare Side Effects: - Angio‑edema involving the face, lips or tongue - Severe hypotension - Acute kidney injury - Hepatic enzyme elevation - Myocardial infarction in susceptible patients - Severe allergic skin reactions (e.g., Stevens‑Johnson syndrome)

Patients should be evaluated for contraindications and monitored during therapy. - Renal impairment: adjust dose or avoid if severe. - Hepatic impairment: use with caution; monitor liver function. - Electrolyte disturbances: check potassium and sodium levels regularly. - Pregnancy: discontinue if pregnancy is confirmed; risk of fetal toxicity. - Elderly patients: start at lower dose and monitor for orthostatic hypotension. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Olmesartanmedoxomil/Amlodipin Viatris may interact with several drug classes.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade (e.g., ACE inhibitors, other ARBs): increased risk of renal dysfunction and hyperkalaemia. - Potassium‑sparing diuretics or supplements: heightened hyperkalaemia risk.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihy‑hypertensive effect and affect renal function. - CYP3A4 inhibitors (e.g., clarithromycin, itraconazole): can raise amlodipine plasma levels. - CYP3A4 inducers (e.g., rifampicin): may reduce amlodipine exposure. - Diuretics: may enhance hypotensive effect, requiring dose adjustment. - Lithium: monitor serum levels as ARBs can increase lithium retention.